Business Wire

DC-MEETINGPLAY/AVENTRI

6.1.2022 16:02:13 CET | Business Wire | Press release

Share
Event Software Leaders MeetingPlay and Aventri Merge; Eric Lochner Named New CEO

Today, market leading event software companies MeetingPlay and Aventri announce that they have merged and received a growth equity investment from Sunstone Partners and Camden Partners. Combining the strengths of both companies, they will forge a new path as the dominant, full-service event software provider.

This new event software powerhouse will blend visionary technology and best-in-class service to close all gaps in the planning process, offering the most complete full-service solution for meetings and events of all sizes, from conferences of 200,000+ to meetings with less than 100 attendees. The combined company will become one of the world’s largest event technology companies, servicing customers on a global scale.

In conjunction with the merger, Eric Lochner has been named Chief Executive Officer of the new company. Eric has over 25 years of experience in building technology and technology-enabled services companies, with an impressive record of mergers and acquisitions. “We are excited to bring these two inventive companies together to create a new cutting-edge experience for the meetings and events industry,” said Lochner. “We have a strong opportunity to deepen the process of hosting in-person, hybrid and virtual events and are excited to be able to better support meeting planners and event organizers while offering a wider range of products and experiences.”

Each year, MeetingPlay and Aventri power a combined total of more than 50,000 events, service over 10,000 companies, and elevate the attendee experience for more than 7 million attendees. The unrivaled creativity, service, and ingenuity of each company will be at the forefront of their new company and brand, which will enable their enterprise customers to grow their businesses with best-in-class events of all types and sizes.

Founded in 2011, MeetingPlay is an award-winning technology pioneer, centered around creating innovative solutions for premier in-person, virtual, and hybrid events. The company is known for pushing the envelope on technology advancements and has successfully powered many of the largest, most complex global events to date across numerous industries.

Aventri is the global leader in data-driven, end-to-end event management solutions for virtual, hybrid, and in-person events. The company was founded in 2008. Today, the award-winning platform provides a suite of premium solutions for the entire event lifecycle, from venue sourcing to event marketing, registration, onsite technology, strategic meetings management, data security and privacy, and ROI reporting.

“Two great companies are coming together, leveraging secular tailwinds to increase market share and expand their innovative software capabilities to benefit top companies and brands,” said Sunstone Partners Co-Founder and Managing Director, Michael Biggee. “We’re delighted to continue partnering with them on their exciting future as one company.”

This news comes at a critical time in the meetings and events industry when planners and organizers are seeking to adopt the benefits of virtual and hybrid gatherings while using fewer software integrations. The two companies will integrate their proprietary software platforms to elevate event experiences through a robust lineup of unmatched products to leading companies in the technology, financial services, travel, hospitality, health services, and association markets. This, paired with the highest level of service, will deliver a richer experience for both planners and attendees, while setting the brand apart from competitors. Highlighted capabilities include:

  • Event Marketing Website and Registration to create a seamless attendee journey from beginning to end.
  • A Virtual and Hybrid Event Platform, which uses novel technology to create lifelike experiences for virtual attendees. The platform provides virtual and onsite attendees with unified engagement features like chat, Q&A, network matchmaking, and video conferencing that enables participants in the same room and across the world to connect instantly.
  • A Mobile App and imaginative Onsite Event Solutions, which enrich the attendee experience start to finish, boost engagement, and deliver ROI metrics, while keeping participants safe.

Co-Founder and former MeetingPlay CEO Joe Schwinger, and Co-Founder and former MeetingPlay COO Lisa Vann will remain with the new company and undertake executive roles to continue enhancing the event technology industry and working with their valued customers. Former Aventri CEO Jim Sharpe will remain a shareholder and advisor to the new company.

For more information about MeetingPlay, visit www.meetingplay.com and follow along on Instagram , Twitter , Facebook and LinkedIn .

For more information about Aventri, visit www.aventri.com and follow along on Instagram , Twitter , Facebook and LinkedIn .

About MeetingPlay
MeetingPlay is a Washington D.C.-based technology company focused on creating groundbreaking solutions for in-person, virtual, and hybrid events. With every meeting and event, MeetingPlay creates transformative experiences that enables their customers, attendees, and sponsors to make valuable, face-to-face connections. Market-leading companies entrust MeetingPlay to solve their biggest event challenges. Learn more at meetingplay.com .

About Aventri
Aventri is the global leader in data-driven, end-to-end event and meeting management solutions for virtual, hybrid, and in-person events. Their award-winning SaaS platform, virtual technology, and best-in-class service offerings have enabled more than 30,000 event professionals annually to plan, promote, deliver, measure, and optimize their events. Aventri’s fully integrated platform’s capabilities include virtual delivery, networking, venue sourcing, registration, marketing, logistics, onsite services, attendee engagement, and data analytics. Headquartered in the United States, the company has offices in the United Kingdom, Europe, and Asia Pacific and has delivered customer events in over 120 countries. Learn more at aventri.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye